Indeed, the first-line treatment for HF relies on angiotensin-converting enzyme (ACE) inhibitors and Ang II receptor blockers, which show promise in blunting cardiac fibrosis (2, 18, 19). This evidence concerns the gene ACE and hydrops fetalis.